G

GE Healthcare

Imaging, monitoring, and healthcare IT solutions

Regulatory Affairs Manager - Global Labeling, PDx

Full-TimePosted on 8/10/2026Deadline 9/14/26
$89.6k - $134.4k/yr+ Performance-based incentive compensation + Cash bonus(es) + Long-term incentives
Senior
Bachelor's
Remote in USA
Remote
Biology & Biotech, Regulatory & Quality (Life Sciences)
No H1B Sponsorship

About the job

Requirements
  • At least 7 years of Regulatory Affairs experience, including significant experience in labeling.
  • Strong knowledge of United States Food and Drug Administration labeling requirements and experience supporting United States regulatory submissions.
  • Experience developing and maintaining United States labeling and/or Core Company Data Sheet.
  • Ability to influence cross-functional teams and manage complex projects.
  • Excellent written and verbal communication skills.
  • The position requires legal authorization to work in the United States.
  • Individuals requiring employment visa sponsorship are not eligible for sponsorship for this opening.
Responsibilities
  • Lead global labeling strategy for assigned products, with primary focus on United States Food and Drug Administration requirements and labeling expectations.
  • Provide labeling input to development programs, lifecycle management activities, and regulatory submissions.
  • Ensure alignment between United States labeling, Core Company Data Sheet, and regional implementation strategies.
  • Lead preparation and review of United States labeling content, including United States Prescribing Information and Food and Drug Administration labeling updates.
  • Support Food and Drug Administration interactions and labeling negotiations.
  • Assess regulatory risks and communicate the impact of Food and Drug Administration feedback on development and commercialization plans.
  • Partner with Clinical, Chemistry, Manufacturing, and Controls, Safety, Medical, Market Access, Commercial, Legal, and Advertising and Promotional teams to develop clear and defensible labeling positions.
  • Translate complex regulatory requirements into business-relevant recommendations.
  • Support labeling governance processes and ensure inspection-ready documentation.
  • Drive timely implementation of labeling changes and continuous process improvement.
  • Contribute to labeling metrics, systems, and best practices across the organization.
  • Support Core Company Data Sheet creation, maintenance, version control, and change-control activities, ensuring United States labeling decisions are assessed for global impact and reflected in global labeling governance.
  • Coordinate with global regulatory leads and regional Regulatory Affairs teams to evaluate local implementation requirements, document deviations or exceptions from the Core Company Data Sheet, and maintain rationale for regional differences.
  • Track implementation of labeling changes across United States and global markets, including milestones, dependencies, approvals, exceptions, and closure status.
  • Maintain labeling trackers, action logs, decision records, and implementation status to support global visibility and inspection readiness.
Desired Qualifications
  • Experience interacting with the Food and Drug Administration on labeling matters.
  • Knowledge of European Union and global labeling requirements.
  • Experience with Veeva Regulatory Information Management or similar regulatory systems.
  • A degree in Life Sciences, Pharmacy, or a related field.

About the company

GE Healthcare Systems provides medical technologies and digital infrastructure to improve diagnosis, treatment, and monitoring of patients. Its products include imaging systems, mobile diagnostic devices, patient monitoring tools, and healthcare IT software that work together as hardware, software, and services to support hospitals, clinics, and researchers. The company differentiates itself with a large, integrated ecosystem, strong focus on AI analytics, and a global service network backed by substantial R&D investment. Its goal is to improve patient outcomes and the efficiency of healthcare delivery by enabling accurate diagnoses, effective treatments, and scaled operations.

Company Size

1-10

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

1892

Get referred to GE Healthcare

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 orders rose 11% and backlog reached a record $23.9 billion.
  • CareIntellect for Operations launched September 2026 with Duke Health and Queen's Health Systems.
  • CE mark and FDA progress for Photonova Spectra expand 2026-2027 commercial momentum.

What critics are saying

  • FDA logged multiple 2026 Class 2 recalls, including AW Server and telemetry systems.
  • Patient Care Solutions remained weak in Q2 2026; management is reviewing a sale.
  • SOFIE closes only after 2027 regulatory approvals; PET supply integration can slip badly.

What makes GE Healthcare unique

  • GE HealthCare combines imaging hardware, radiopharmaceuticals, and workflow software across hospitals.
  • Photonova Spectra and Vivid 2026 show premium innovation plus AI-enabled clinical automation.
  • SOFIE's 21 cyclotrons extend GE HealthCare into radiotracer manufacturing, not just scanners.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Relocation Assistance

Company News

Business Wire
Oct 5th, 2026
GE HealthCare to acquire SOFIE Biosciences for $945M to expand US radiopharmaceutical supply

GE HealthCare has agreed to acquire SOFIE Biosciences, a US-based contract manufacturer of PET radiopharmaceuticals, for $945 million in cash. The deal with seller Trilantic North America is expected to close in the first half of 2027, subject to regulatory approvals. SOFIE Biosciences operates 15 contract manufacturing sites with 21 cyclotrons across the US, plus a theranostics-focused development and manufacturing facility. The acquisition establishes GE HealthCare's presence in the time-critical "final mile" of US PET radiopharmaceutical supply. The PET radiopharmaceutical market is expanding rapidly with approximately 20 PET radiotracers and over 30 radiotherapeutics currently under development. SOFIE Biosciences' portfolio includes a Phase III FAPI asset for which GE HealthCare already holds non-US rights. GE HealthCare estimates the transaction will be accretive to revenue growth, earnings margin, and earnings per share in the first full year of ownership.

PR Newswire
Sep 30th, 2026
AsiaMedic first in ASEAN to deploy GE HealthCare's MR31 deep learning MRI platform

AsiaMedic has become the first site in ASEAN to implement MR31, GE HealthCare's latest generation MRI platform featuring deep learning technology. The Singapore-based imaging centre is among the earliest adopters in Asia Pacific. MR31 incorporates deep learning technologies that reduce scan times and enable detailed examinations across neurological, musculoskeletal and nerve imaging. Sonic DL for 3D delivers up to 12 times scan acceleration, reducing examination times across brain, spine, orthopaedic and body scans. The platform also supports high-quality prostate MRI imaging. AIR Recon DL Phase Correction provides improved visualisation of clinically significant lesions, whilst high-resolution T2-weighted imaging aids lesion localisation for prostate fusion biopsy planning. Shorter scan times mean reduced patient time in scanners and may help decrease repeat examinations caused by movement.

Associated Press
Sep 22nd, 2026
GE HealthCare raises quarterly dividend 14% to $0.04 per share for Q3 2026

GE HealthCare Technologies announced a 14% dividend increase for the third quarter of 2026. The company's board declared a cash dividend of $0.04 per share, up from the previous quarter. The dividend will be paid on 13 November 2026 to shareholders of record as of 23 October 2026. GE HealthCare is a global healthcare solutions provider specialising in medical technology, pharmaceutical diagnostics, and AI-enabled software solutions. The company operates a $20.6 billion business with approximately 54,000 employees worldwide, serving the healthcare industry through its Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions segments.

Yahoo Finance
Sep 15th, 2026
GE HealthCare launches AI tool to forecast hospital capacity bottlenecks 72 hours ahead

GE HealthCare has launched CareIntellect for Operations, an AI-powered software application that helps health systems forecast capacity constraints up to 72 hours ahead. The solution analyses hundreds of patient and operational data points to predict bottlenecks and recommend actions to optimise capacity and throughput. The Queen's Health Systems and Duke Health will be the first to implement the application. It uses two proprietary AI models: the Pressure Forecast model, which predicts resource constraints across hospitals and departments, and the Estimated Day of Discharge model, which predicts when patients will be discharged. The tool addresses operational challenges as US inpatient volumes rose 5.3% in 2025, requiring health systems to manage increased demand whilst facing staffing shortages and rising costs.

Yahoo Finance
Sep 1st, 2026
GE HealthCare secures CE mark for Photonova Spectra photon-counting CT system

GE HealthCare has received CE mark approval for its Photonova Spectra photon-counting computed tomography system, enabling commercial sales in markets recognising CE marking. The clearance follows US Food and Drug Administration approval and Japanese regulatory clearance in March 2026. The system uses GE HealthCare's Deep Silicon detector technology to deliver ultra-high definition spectral and spatial imaging. It processes data volumes up to 50 times greater than conventional CT systems, utilising Nvidia's accelerated computing platform. Clinical collaborations are underway at UZ Brussel in Belgium and Rigshospitalet in Denmark to evaluate the system across cardiology, neurology, oncology and musculoskeletal imaging. The CE mark follows more than $5 billion in innovation investment by GE HealthCare.

INACTIVE